Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Antidiabetic compound effectively treats obesity in patients with altered glucose metabolism

June 11, 1999

Cannabinoid receptor antagonist SR-141716 shows potential as antiobesity agent

June 11, 1999

BTS-71091 induces satiety in rats

June 11, 1999

Vivus announces another European launch for Muse

June 10, 1999

Novel MTP inhibitors for lipid and other metabolic disorders

June 10, 1999

Sankyo teams up with Warner-Lambert to develop new antidiabetic agent

June 10, 1999

Sankyo obtains rights to copromote itavastatin in Japan, exclusive R&D and marketing rights in U.S.

June 10, 1999

First launches announced for Asta Medica's LHRH antagonist

June 9, 1999

Phase III study supports efficacy and safety of Hextend in treatment of hypovolemia

June 9, 1999

Academic researchers move closer to the development of an artificial pancreas

June 9, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 1, 2026.
TROP2 ADCs progress into first-line for lung, breast cancers
BioWorld
Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for...
New evidence links autoimmunity to long COVID symptoms
BioWorld
Recent findings are reshaping current understanding of the post-infection landscape of SARS-CoV-2. Although previous studies had already suggested that...
Breakthrough as GSK’s bepirovirsen clears 19% of chronic hep B infections
BioWorld
GSK plc has announced a breakthrough in the treatment of chronic hepatitis B, reporting a functional cure rate of 19% across two phase III trials of its antisense...
BMS’ mezigdomide doubles PFS in multiple myeloma
BioWorld
Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with...